129 related articles for article (PubMed ID: 14656874)
1. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies.
Linden M; Kirchhof N; Carlson C; Van Ness B
Blood; 2004 Apr; 103(7):2779-86. PubMed ID: 14656874
[TBL] [Abstract][Full Text] [Related]
2. Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.
Linden MA; Kirchhof N; Carlson CS; Van Ness BG
Exp Hematol; 2012 Mar; 40(3):216-27. PubMed ID: 22120021
[TBL] [Abstract][Full Text] [Related]
3. ABL-MYC retroviral infection elicits bone marrow plasma cell tumors in Bcl-X(L) transgenic mice.
Linden M; Kirchhof N; Kvitrud M; Van Ness B
Leuk Res; 2005 Apr; 29(4):435-44. PubMed ID: 15725478
[TBL] [Abstract][Full Text] [Related]
4. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma.
Boylan KL; Gosse MA; Staggs SE; Janz S; Grindle S; Kansas GS; Van Ness BG
Cancer Res; 2007 May; 67(9):4069-78. PubMed ID: 17483317
[TBL] [Abstract][Full Text] [Related]
5. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice.
Cheung WC; Kim JS; Linden M; Peng L; Van Ness B; Polakiewicz RD; Janz S
J Clin Invest; 2004 Jun; 113(12):1763-73. PubMed ID: 15199411
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Bcl-2 or Bcl-XL transgenes and photoreceptor degeneration.
Joseph RM; Li T
Invest Ophthalmol Vis Sci; 1996 Nov; 37(12):2434-46. PubMed ID: 8933760
[TBL] [Abstract][Full Text] [Related]
7. Perturbation of B-cell development in mice overexpressing the Bcl-2 homolog A1.
Chuang PI; Morefield S; Liu CY; Chen S; Harlan JM; Willerford DM
Blood; 2002 May; 99(9):3350-9. PubMed ID: 11964303
[TBL] [Abstract][Full Text] [Related]
8. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes.
Tsimbouri P; Drotar ME; Coy JL; Wilson JB
Oncogene; 2002 Aug; 21(33):5182-7. PubMed ID: 12140768
[TBL] [Abstract][Full Text] [Related]
9. Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival.
Strasser A; Elefanty AG; Harris AW; Cory S
EMBO J; 1996 Aug; 15(15):3823-34. PubMed ID: 8670887
[TBL] [Abstract][Full Text] [Related]
10. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
11. Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Gil VS; Bhagat G; Howell L; Zhang J; Kim CH; Stengel S; Vega F; Zelent A; Petrie K
Dis Model Mech; 2016 Dec; 9(12):1483-1495. PubMed ID: 27799148
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
Blood; 2017 Apr; 129(14):1969-1979. PubMed ID: 28151428
[TBL] [Abstract][Full Text] [Related]
13. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice.
Grillot DA; Merino R; Pena JC; Fanslow WC; Finkelman FD; Thompson CB; Nunez G
J Exp Med; 1996 Feb; 183(2):381-91. PubMed ID: 8627151
[TBL] [Abstract][Full Text] [Related]
14. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.
Kelly PN; Puthalakath H; Adams JM; Strasser A
Blood; 2007 Jun; 109(11):4907-13. PubMed ID: 17317859
[TBL] [Abstract][Full Text] [Related]
15. Generation of precursor, immature, and mature murine B1-cell lines from c-myc/bcl-xL-overexpressing pre-BI cells.
Wolf I; Bouquet C; Naumann F; Melchers F
Eur J Immunol; 2017 May; 47(5):911-920. PubMed ID: 28294314
[TBL] [Abstract][Full Text] [Related]
16. Cyclin E and Bcl-xL cooperatively induce cell cycle progression in c-Rel-/- B cells.
Cheng S; Hsia CY; Leone G; Liou HC
Oncogene; 2003 Nov; 22(52):8472-86. PubMed ID: 14627988
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
[TBL] [Abstract][Full Text] [Related]
18. Transgene expression of bcl-xL permits anti-immunoglobulin (Ig)-induced proliferation in xid B cells.
Solvason N; Wu WW; Kabra N; Lund-Johansen F; Roncarolo MG; Behrens TW; Grillot DA; Nunez G; Lees E; Howard M
J Exp Med; 1998 Apr; 187(7):1081-91. PubMed ID: 9529324
[TBL] [Abstract][Full Text] [Related]
19. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.
Strasser A; Harris AW; Bath ML; Cory S
Nature; 1990 Nov; 348(6299):331-3. PubMed ID: 2250704
[TBL] [Abstract][Full Text] [Related]
20. Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc.
Swanson PJ; Kuslak SL; Fang W; Tze L; Gaffney P; Selby S; Hippen KL; Nunez G; Sidman CL; Behrens TW
J Immunol; 2004 Jun; 172(11):6684-91. PubMed ID: 15153484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
